Geographic Atrophy Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Manufacturers, Companies by DelveInsight

Geographic Atrophy companies are Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics), and others.
(Albany, USA) DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Geographic Atrophy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Geographic Atrophy market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Geographic Atrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Geographic Atrophy market.

Request for a Free Sample Report @ Geographic Atrophy Market Forecast [https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Geographic Atrophy Market Report are:

* According to DelveInsight, Geographic Atrophy market size is expected to grow at a decent CAGR by 2034.
* Leading Geographic Atrophy companies working in the market are Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics), and others.
* Key Geographic Atrophy Therapies expected to launch in the market are Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech/ Roche (RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), NGMBiopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche (OpRegen), Novartis (PPY988/GT005), Regenerative Patch Technologies (CPCB-RPE1), Luxa Biotechnology (RPESC-RPE-4W) and others.
* In April 2025, Boehringer Ingelheim announced a study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
* In April 2025, Janssen Research & Development LLC conducted a phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
* In April 2025, Hoffmann-La Roche conducted a study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
* In February 2025, Astellas Pharma announced that the FDA approved expanded prescribing information for IZERVAYTM (avacincaptad pegol intravitreal solution) for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The approval removes the limitation on the duration of dosing, offering physicians and patients more flexibility in managing GA. On March 2024, Genentech announced results of A Phase IIa, Multicenter, Open-Label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
* On April 2024, Boehringer Ingelheim announced results of a study about the Safety, Tolerability, and Pharmacokinetics of Intravitreal Single Rising Doses and Multiple Doses of BI 771716 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized).
* On February 2024, Apellis Pharmaceuticals announced results of a Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
* On March 2024, Janssen Research & Development announced results of a Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy Overview

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss. Geographic Atrophy primarily affects the macula, the central part of the retina responsible for sharp, central vision. Geographic Atrophy is characterized by the gradual degeneration of retinal cells, retinal pigment epithelium (RPE), and the underlying choriocapillaris. Geographic Atrophy typically progresses over time and can significantly impact daily activities like reading, recognizing faces, and driving.

Geographic Atrophy is a leading cause of vision impairment in older adults and currently has no approved cure. Geographic Atrophy prevalence increases with age and is often detected in individuals over 60. Geographic Atrophy symptoms may include blurred vision, dark spots in the central vision, and difficulty adapting to low-light environments. Geographic Atrophy diagnosis is confirmed through advanced imaging techniques such as optical coherence tomography (OCT) and fundus autofluorescence (FAF).

Geographic Atrophy treatment options are limited, but ongoing research aims to slow its progression. Geographic Atrophy management includes regular monitoring, low-vision aids, and emerging therapies targeting complement pathway inhibition. Geographic Atrophy awareness is crucial for early detection and intervention. Geographic Atrophy research continues to explore innovative treatments that may preserve vision and enhance the quality of life for affected individuals.

Learn more about Geographic Atrophy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Geographic Atrophy Treatment Market [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Geographic Atrophy Market

The Geographic Atrophy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Geographic Atrophy market trends by analyzing the impact of current Geographic Atrophy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Geographic Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Geographic Atrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Geographic Atrophy market in 7MM is expected to witness a major change in the study period 2020-2034.

Geographic Atrophy Epidemiology

The Geographic Atrophy epidemiology section provides insights into the historical and current Geographic Atrophy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Geographic Atrophy market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Geographic Atrophy Epidemiology @ Geographic Atrophy Market Dynamics [https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Geographic Atrophy Drugs Uptake

This section focuses on the uptake rate of the potential Geographic Atrophy drugs recently launched in the Geographic Atrophy market or expected to be launched in 2020-2034. The analysis covers the Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Geographic Atrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Geographic Atrophy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Geographic Atrophy Pipeline Development Activities

The Geographic Atrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Geographic Atrophy key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Geographic Atrophy pipeline development activities @ Geographic Atrophy Companies and medication [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Geographic Atrophy Therapeutics Assessment

Major key companies are working proactively in the Geographic Atrophy Therapeutics market to develop novel therapies which will drive the Geographic Atrophy treatment markets in the upcoming years are Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics), and others.

Learn more about the emerging Geographic Atrophy therapies & key companies @ Geographic Atrophy Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Geographic Atrophy Report Key Insights

1. Geographic Atrophy Patient Population

2. Geographic Atrophy Market Size and Trends

3. Key Cross Competition in the Geographic Atrophy Market

4. Geographic Atrophy Market Dynamics (Key Drivers and Barriers)

5. Geographic Atrophy Market Opportunities

6. Geographic Atrophy Therapeutic Approaches

7. Geographic Atrophy Pipeline Analysis

8. Geographic Atrophy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Geographic Atrophy Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Geographic Atrophy Competitive Intelligence Analysis

4. Geographic Atrophy Market Overview at a Glance

5. Geographic Atrophy Disease Background and Overview

6. Geographic Atrophy Patient Journey

7. Geographic Atrophy Epidemiology and Patient Population

8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Geographic Atrophy Marketed Products

12. Geographic Atrophy Emerging Therapies

13. Geographic Atrophy Seven Major Market Analysis

14. Attribute Analysis

15. Geographic Atrophy Market Outlook (7 major markets)

16. Geographic Atrophy Access and Reimbursement Overview

17. KOL Views on the Geographic Atrophy Market

18. Geographic Atrophy Market Drivers

19. Geographic Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=geographic-atrophy-treatment-market-2034-ema-pdma-fda-approvals-medication-nice-approvals-clinical-trials-revenue-statistics-therapies-manufacturers-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.